Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Beneficiaries using Tricare Prime, Tricare Standard and premium-based plans will continue to have access but must meet specific criteria.

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

More than 2,000 lawsuits are now targeting the makers of Ozempic and Zepbound, with patients claiming the drugs caused dangerous and sometimes permanent health problems. The cases, consolidated in ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Her copay for Zepbound has been around $10 per month since she started the drug in March. Skala said she has lost 52 pounds and noticed "profound improvements" in her mental health, sleep and ...

Zepbound brought in sales of $176 million through Dec. 31, according to Lilly. Novo Nordisk, the Danish manufacturer of Ozempic and Wegovy, also has raked in billions from the sale of the weight ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.